Journal
CURRENT OPINION IN CELL BIOLOGY
Volume 21, Issue 2, Pages 317-324Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.ceb.2009.01.015
Keywords
-
Categories
Funding
- UK Medical Research Council
- Royal Society
- AstraZeneca
- Boehringer Ingelheim
- GlaxoSmithKline
- Merek-Serono
- Pfizer
- Medical Research Council [MC_EX_G0800765] Funding Source: researchfish
- MRC [MC_EX_G0800765] Funding Source: UKRI
Ask authors/readers for more resources
In recent years, protein kinases have become the pharmaceutical industry's most studied class of drug target, and some 10 protein kinase inhibitors have so far been approved for the treatment of cancer. However, whether safe drugs that modulate protein kinase activities can also be developed for the treatment of chronic diseases, where they may need to be taken for decades, is an issue that is still unresolved. A number of compounds that inhibit the p38 alpha MAPK have entered clinical trials for the treatment of rheumatoid arthritis and psoriasis, but side effects have prevented their progression to Phase III clinical trials. Here I briefly review the potential problems in targeting p38 MAPK and discuss other protein kinases that regulate the innate immune system, such as Tp12, MAPKAP-K2/3, MSK1/2 and IRAK4, which may be better targets for the treatment of chronic inflammatory diseases, and NIK, which is an attractive target for the treatment of multiple myeloma, a late stage B-cell malignancy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available